RecruitingPhase 2NCT04991103
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Studying Amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Alabama at Birmingham
- Principal Investigator
- Susan Bal, MDUniversity of Alabama at Birmingham
- Intervention
- DaraVRD/DaraVCD(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (1)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04991103 on ClinicalTrials.govOther trials for Amyloidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07560306[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid CardiomyopathyBrigham and Women's Hospital
- RECRUITINGNCT07494656A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in GermanyPfizer
- RECRUITINGPHASE2NCT07285044The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasMayo Clinic
- RECRUITINGNCT07218705A Study Of MCG In Cardiac AmyloidosisMayo Clinic
- ENROLLING BY INVITATIONPHASE2NCT06723015Tau PET Outcomes With Anti-amyloid ImmunotherapiesMayo Clinic
- RECRUITINGNCT07213297Comprehensive Program for Hereditary Transthyretin AmyloidosisHospital de Alta Complejidad en Red
- RECRUITINGPHASE1NCT06790394Test-retest Study With [18F]FBB in Cardiac AmyloidosisLife Molecular Imaging GmbH
- RECRUITINGNANCT07112066Multimodality Cardiac Imaging for Disease Progression in ATTR-CMDominik Benz